Skip to content

Free cash flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
AbbVie logo
AbbVieABBV
$3.56B+155%
Stryker logo
StrykerSYK
$415M+227%
Medtronic logo
MedtronicMDT
$2.09B+0.8%
Globus Medical logo
Globus MedicalGMED
Solventum logo
SolventumSOLV

Other financials

Income statement

See full
Revenue$59.9M+44.7%
Gross profit$42.3M+52.2%
Operating income-$6.5M+61.6%
Net income-$13.4M+35.4%
EPS (diluted)-$0.45+35.7%

Balance sheet

See full
Cash & equivalents$68.1M-1.6%
Total debt$252.7M+12.0%
Total equity$14.8M-61.7%
Total assets$351.0M+5.3%

Cash flow

See full
Operating cash flow-$4.3M+79.2%
CapEx$1.9M+146%

Valuation

See full
Market cap$2.56B+41.4%
Enterprise value$2.75B+38.7%
P/S11.2×+0.5×

Profitability

See full
Gross margin70.1%+3.7pp
Operating margin-12.4%-4.8pp
Net margin-19.1%-7.4pp
FCF margin-18.1%-6.6pp

Returns & leverage

See full
Return on equity-164%-17.8pp
Debt / equity17.1×+11.2×
Current ratio-0.4×

Where this comes from

Calculated from Establishment Labs’s reported figures.

The official record: Establishment Labs’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Establishment Labs's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Establishment Labs's free cash flow?
Establishment Labs (ESTA) reported free cash flow of -$6.16M in Q1 2026.
How has Establishment Labs's free cash flow changed year-over-year?
Establishment Labs's free cash flow increased by 71.3% year-over-year, from -$21.48M to -$6.16M.
What is the long-term trend for Establishment Labs's free cash flow?
Over 4 years (2021 to 2025), Establishment Labs's free cash flow has grown at a 17.4% compound annual growth rate (CAGR), from -$29.96M to -$56.94M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.